Targeting IL-23 Succeeds in Psoriatic Arthritis
The monoclonal antibody risankizumab (Skyrizi) showed significant efficacy for psoriatic arthritis (PsA) in two phase III randomized trials, a researcher reported. In the KEEPSAKE 1 and 2 trials, 1,407 patients with active PsA were randomly assigned to receive subcutaneous risankizumab, 150 mg, or placebo at baseline and then at weeks 4 and 16. On the […]